Breast Cancer Clinical Trial
Official title:
Rapid Evaporative Ionisation Mass Spectrometry for Examination of Circumferential Surgical Excision Margins
REI-EXCISE is a multicentre, prospective, non-randomised feasibility study, aimed to evaluate the diagnostic accuracy of rapid ionisation mass spectroscopy using an iKnife device. The iKnife will collect vapour, a by-product of surgery, which will pass through the mass spectrometer machine for analysis in order to evaluate what is "normal" and what is "cancerous" breast tissue.
There is an urgent need to address high rates of close or positive margins and re-operative
breast cancer surgery, which commonly results from the inability of the surgeon to rapidly
and reliably evaluate resection margin status intra-operatively.
This study therefore seeks to address this problem by aiming to develop a method for near
real time, in vivo intra-operative tissue classification that may be used by breast surgeons
as an intelligent knife (or "iKnife") to better guide oncological margin control. The method
known as Rapid Evaporative Ionisation Mass Spectrometry (REIMS) technology uses mass
spectrometric and chemometric analysis of the tissue specific ionic content of the surgical
diathermy smoke plume for the rapid identification of dissected breast tissues.
There are no additional treatment interventions as part of REI-EXCISE. The main study
procedures are breast conserving surgery using the REIMS iKnife for mass spectral analysis of
each surgical margin and correlation between the results of a software recognition algorithm
that capitalised on the spectral data (i.e. iKnife margin = positive / negative) with
conventional histopathological assessment. False positive iKnife data will be further
interrogated with digital droplet polymerase chain reaction and imprint cytology assessment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03095352 -
A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
|
||
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Recruiting |
NCT03667716 -
COM701 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03709134 -
Genomic Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment
|
||
Recruiting |
NCT02894398 -
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
|
Phase 2 | |
Active, not recruiting |
NCT01857193 -
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
|
Phase 1 | |
Recruiting |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Active, not recruiting |
NCT02139358 -
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03615573 -
Survey Study: Financial Impact of Breast Cancer Treatment
|
||
Completed |
NCT03323333 -
Psychosocial Intervention Pilot for Partners in BRCA Testing
|
N/A | |
Terminated |
NCT01649258 -
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
|
Phase 1 | |
Withdrawn |
NCT03285607 -
MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
|
Phase 1 | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Recruiting |
NCT01992432 -
Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)
|
||
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A | |
Completed |
NCT00759785 -
A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)
|
Phase 1 |